Evidence map›Paper›PMID 36255249›Full record

ArticleJNCI cancer spectrum2022

The Association Between Financial Toxicity and Treatment Regret in Men With Localized Prostate Cancer.

Daniel D Joyce, Christopher J D Wallis, Li-Ching Huang, Karen E Hoffman, Zhiguo Zhao, Tatsuki Koyama, Michael Goodman, Ann S Hamilton, Xiao-Cheng Wu, Lisa E Paddock and 8 more

3 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07032584 narecruitingnot on this mapstarted 2025, after this paper: background citation

Impact of Multimodal Telerehabilitation on Reducing Disparities in Rural Survivors of Metastatic Prostate Cancer

TypeinterventionalSponsorUniversity of UtahRan2025 to 2029Enrolled74ConditionsProstate Cancer, Metastatic Prostate Cancer, Androgen Deprivation TherapyArmsTelerehabilitation Intervention
NCT07093177 narecruitingnot on this mapstarted 2026, after this paper: background citation

Multimodal Telerehabilitation of Rural Patients With Advanced Prostate Cancer

TypeinterventionalSponsorUniversity of UtahRan2026 to 2028Enrolled30ConditionsProstate CancerArmsTelerehabilitation Unit
NCT07390071 narecruitingnot on this mapstarted 2025, after this paper: background citation

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

TypeinterventionalSponsorUniversity of UtahRan2025 to 2029Enrolled40ConditionsLymphoma, Myeloma, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity SyndromeArmsHome Automated Telemanagement (HAT) Patient Unit
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 2 countries.

Daniel D JoyceDepartment of Urology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-4365-8622
Christopher J D WallisDepartment of Surgery, Division of Urology, University of Toronto, Toronto, ON, Canada.
Li-Ching HuangDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Karen E HoffmanDepartment of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Zhiguo ZhaoDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Tatsuki KoyamaDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Michael GoodmanDepartment of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA.ORCID 0000-0001-6956-6879
Ann S HamiltonDepartment of Population and Public Health Sciences, Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA.
Xiao-Cheng WuDepartment of Epidemiology, Louisiana State University New Orleans School of Public Health, New Orleans, LA, USA.
Lisa E PaddockDepartment of Epidemiology, Cancer Institute of New Jersey, Rutgers Health, New Brunswick, NJ, USA.
Antoinette StroupDepartment of Epidemiology, Cancer Institute of New Jersey, Rutgers Health, New Brunswick, NJ, USA.
Matthew R CooperbergDepartment of Urology, University of California, San Francisco, CA, USA.ORCID 0000-0003-4339-6685
Mia HashibeDepartment of Family and Preventative Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.ORCID 0000-0002-6903-2049
Brock B O'NeilDepartment of Urology, University of Utah Health, Salt Lake City, UT, USA.
Sherrie H KaplanDepartment of Medicine, University of California Irvine, Irvine, CA, USA.
Sheldon GreenfieldDepartment of Medicine, University of California Irvine, Irvine, CA, USA.
David F PensonDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Daniel A BarocasDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Vanderbilt University Medical Center · USRutgers, The State University of New Jersey · USUniversity of California, Irvine · USUniversity of Utah · USEmory University · USLouisiana State University · USMayo Clinic in Arizona · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USUniversity of Southern California · USUniversity of Toronto · CAVA Tennessee Valley Healthcare System · US

Funding

Comparative Effectiveness of Treatments for Localized Prostate CancerR01HS019356 · AHRQ · VANDERBILT UNIVERSITY · PI PENSON, DAVID F. · 2010 to 2010
$7.6M
10-year Comparative Effectiveness and Harms of Treatments for Prostate CancerR01CA230352 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BAROCAS, DANIEL A · 2019 to 2023
$3.1M
Comparative Effectiveness of Modern Therapies for Localized Prostate CancerR01HS022640 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PENSON, DAVID F. · 2013 to 2013
$1.8M
AHRQ HHS R01 HS019356AHRQ HHS R01 HS022640NCI NIH HHS R01 CA230352
6 · The paper itself

Abstract

backgroundFinancial toxicity is emerging as an important patient-centered outcome and is understudied in prostate cancer patients. We sought to understand the association between financial burden and treatment regret in men with localized prostate cancer to better evaluate the role of financial discussions in patient counseling.

methodsUtilizing the Comparative Effectiveness Analysis of Surgery and Radiation dataset, we identified all men accrued between 2011 and 2012 who underwent surgery, radiation, or active surveillance for localized prostate cancer. Financial burden and treatment regret were assessed at 3- and 5-year follow-up. The association between financial burden and regret was assessed using multivariable longitudinal logistic regression controlling for demographic and disease characteristics, treatment, functional outcomes, and patient expectations.

resultsOf the 2924 eligible patients, regret and financial burden assessments for 3- and/or 5-year follow-up were available for 81% (n = 2359). After adjustment for relevant covariates, financial burden from "finances in general" was associated with treatment regret at 3 years (odds ratio [OR] = 2.47, 95% confidence interval [CI] = 1.33 to 4.57; P = .004); however, this association was no longer statistically significant at 5-year follow-up (OR = 1.19, 95% CI = 0.56 to 2.54; P = .7).

conclusionsIn this population-based sample of men with localized prostate cancer, we observed associations between financial burden and treatment regret. Our findings suggest indirect treatment costs, especially during the first 3 years after diagnosis, may impact patients more profoundly than direct costs and are important for inclusion in shared decision making.

Indexed as

Decision Making, SharedProstatic NeoplasmsHumansMale

Identifiers

PMID36255249
PMCPMC9731205
OpenAlexW4306732496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.